Successful suppression using Rituximab of a factor VIII inhibitor in a boy with severe congenital haemophilia: An example of a significant decrease of treatment costs

Thrombosis and Haemostasis

Volumn 95, Issue 2, 2006, Pages 386-387

  Mateo, Jose ^a   Badell, Isabel ^a   Forner, Ruth ^a   Borrell, Montserrat ^a   Tizzano, Eduardo ^a   Fontcuberta, Jordi ^a  

^a HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 8 ANTIBODY; BLOOD CLOTTING FACTOR 8 CONCENTRATE; BLOOD CLOTTING FACTOR 8 INHIBITOR; DIPHENHYDRAMINE; FANHDI; HYDROCORTISONE; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RECOMBINANT BLOOD CLOTTING FACTOR 8; RITUXIMAB; VON WILLEBRAND FACTOR;

ANTIBODY TITER; ARTICLE; CASE REPORT; DISEASE SEVERITY; DRUG COST; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG INFUSION; DRUG SUBSTITUTION; DYSPNEA; ECONOMIC EVALUATION; HEALTH CARE COST; HEMOPHILIA A; HUMAN; HYPOTENSION; INFECTION; INFORMED CONSENT; MALE; MUSCLE HEMATOMA; PRESCHOOL CHILD; PRIORITY JOURNAL; PRURITUS; REMISSION; TACHYCARDIA; TREATMENT OUTCOME;

EID: 33645548972     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1612589     Document Type: Article

References (8)

1. Scharrer I, Bray GL, Neutzling O. Incidence of inhibitors in haemophilia A patients. A review of recent studies of recombinant and plasma-derived Factor VIII concentrates. Haemophilia 1999; 5: 145-54.
2. Knight C, Paisley S, Wight J et al. Economic modeling of different treatment strategies for haemophilia A with high-responding inhibitors. Haemophilia 2003; 9: 521-40.
3. Virgolini L, Marzocchi V. Rituximab in autoimmune diseases. Biomed Pharmacother 2004; 58: 299-309.
4. Auerswald G, Spranger T, Brackmann HH. The role of plasma-derived Factor VIII/von Willebrand Factor concentrates in the treatment of Hemophilia A patients. Haematologica 2003 (suppl 9): 21-5.
5. Wiestner A, Cho HJ, Asch AS et al. Rituximab in the treatment of acquired Factor VIII inhibitors. Blood 2002; 100: 3426-8.
6. Mathias M, Khair K, Hann I et al. Rituximab in the treatment of alloimmune Factor VIII and IX antibodies in two children with severe haemophilia. Br J Haematol 2004; 125: 366-8.
7. Haya S, López MF, Aznar JA et al. and the Spanish Immune Tolerance Group. Immune tolerance treatment in haemophilia patients with inhibitors: the Spanish Registry. Haemophilia 2001; 7: 154-9.
8. Freiburghaus C, Berntorp E, Ekman M et al. Tolerance induction using the Malmo treatment model 1982-1995. Haemophilia 1999; 5: 32-9.